Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke

Atherosclerosis

Volumn 204, Issue 2, 2009, Pages

  Lemaitre, Rozenn N ^a   Rice, Kenneth ^b   Marciante, Kristin ^a   Bis, Joshua C ^a   Lumley, Thomas S ^b   Wiggins, Kerri L ^a   Smith, Nicholas L ^b,c   Heckbert, Susan R ^b   Psaty, Bruce M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Eicosanoic acids; Epidemiology; Genetic polymorphism; Ischemic stroke; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN SYNTHASE; THROMBOXANE SYNTHASE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHI SQUARE TEST; CONTROLLED STUDY; FEMALE; GENE REPLICATION; GENETIC VARIABILITY; GENOTYPE; GROUPS BY AGE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TIME;

ADULT; AGED; ARACHIDONATE LIPOXYGENASES; ASPIRIN; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOXANE-A SYNTHASE;

EID: 67349271287     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.10.011     Document Type: Article

References (32)

1. Davi G., and Patrono C. Platelet activation and atherothrombosis. N Engl J Med 357 (2007) 2482-2494
2. Gross S., Tilly P., Hentsch D., Vonesch J.L., and Fabre J.E. Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 204 (2007) 311-320
3. Peters-Golden M., and Henderson Jr. W.R. Leukotrienes. N Engl J Med 357 (2007) 1841-1854
4. Cipollone F., Toniato E., Martinotti S., et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291 (2004) 2221-2228
5. Colaizzo D., Fofi L., Tiscia G., et al. The COX-2 G/C -765 polymorphism may modulate the occurrence of cerebrovascular ischemia. Blood Coagul Fibrinolysis 17 (2006) 93-96
6. Orbe J., Beloqui O., Rodriguez J.A., et al. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin Chim Acta 368 (2006) 138-143
7. Hegener H.H., Diehl K.A., Kurth T., et al. Polymorphisms of prostaglandin-endoperoxide synthase 2 gene, and prostaglandin-E receptor 2 gene, C-reactive protein concentrations and risk of atherothrombosis: a nested case-control approach. J Thromb Haemost 4 (2006) 1718-1722
8. Lee C.R., North K.E., Bray M.S., et al. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 83 (2008) 52-60
9. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
10. Helgadottir A., Gretarsdottir S., St Clair D., et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 76 (2005) 505-509
11. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
12. Lohmussaar E., Gschwendtner A., Mueller J.C., et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 36 (2005) 731-736
13. Koch W., Hoppmann P., Mueller J.C., Schomig A., and Kastrati A. No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. Genet Med 9 (2007) 123-129
14. Meschia J.F., Brott T.G., Brown Jr. R.D., et al. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Ann Neurol 58 (2005) 351-361
15. Zee R.Y., Cheng S., Hegener H.H., Erlich H.A., and Ridker P.M. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 37 (2006) 2007-2011
16. Reilly K.B., Srinivasan S., Hatley M.E., et al. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem 279 (2004) 9440-9450
17. Psaty B.M., Heckbert S.R., Koepsell T.D., et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274 (1995) 620-625
18. Psaty B.M., Smith N.L., Heckbert S.R., et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 287 (2002) 1680-1689
19. Pearce N. What does the odds ratio estimate in a case-control study?. Int J Epidemiol 22 (1993) 1189-1192
20. Carlson C.S., Eberle M.A., Rieder M.J., et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74 (2004) 106-120
21. French B., Lumley T., Monks S.A., et al. Simple estimates of haplotype relative risks in case-control data. Genet Epidemiol 30 (2006) 485-494
22. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (2004) 234S-264S
23. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
24. Nakayama T., Soma M., Saito S., et al. Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction. Am Heart J 143 (2002) 797-801
25. Nakayama T., Soma M., Rehemudula D., et al. Association of 5′ upstream promoter region of prostacyclin synthase gene variant with cerebral infarction. Am J Hypertens 13 (2000) 1263-1267
26. Kohsaka S., Volcik K.A., Folsom A.R., et al. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196 (2008) 926-930
27. Berger J.S., Roncaglioni M.C., Avanzini F., et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006) 306-313
28. Sanmuganathan P.S., Ghahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 (2001) 265-271
29. Murakami M., Naraba H., Tanioka T., et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275 (2000) 32783-32792
30. Cipollone F., Prontera C., Pini B., et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104 (2001) 921-927
31. Gomez-Hernandez A., Martin-Ventura J.L., Sanchez-Galan E., et al. Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. Atherosclerosis 187 (2006) 139-149
32. Assimes T.L., Knowles J.W., Priest J.R., et al. A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. Atherosclerosis 198 (2008) 136-144